Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
BMJ Open|February 27, 2023
Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trialMads M Helsted, Lærke S Gasbjerg, Tina Vilsbøll, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|December 21, 2025
Phosphodiesterase-4 Inhibition as a Potential Therapeutic Strategy in the Management of Obesity: a ReviewAske Nicolai Høck, Petur Thorri Olafsson, Ida M Gether, et al.
Peptides|April 5, 2024
Targeting the GLP-2 receptor in the management of obesityThorir G Pálsson, Hannah Gilliam-Vigh, Benjamin A H Jensen, et al.
Diabetes Care|March 23, 2022
Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover TrialCasper K Nielsen, Caroline C Øhrstrøm, Urd L Kielgast, et al.
Physiological Reviews|July 28, 2025
Proglucagon-derived Peptides: Human Physiology and Therapeutic PotentialLærke S Gasbjerg, Casper K Nielsen, Malte P Suppli, et al.
Diabetes Care|October 11, 2023
Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled TrialCasper K Nielsen, Caroline C Øhrstrøm, Inas J K Houji, et al.
Journal of the Endocrine Society|January 16, 2026
Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy MenNikolaj E Sørum, Tore Magnussen, Nina L Hansen, et al.
Diabetes, Obesity & Metabolism|October 10, 2025
Acute effects of GIP and GLP-1 receptor antagonism in totally pancreatectomized individuals: A randomized double-blind, placebo-controlled crossover studyLiva S L Krogh, Mads M Helsted, Anders Englund, et al.
The Lancet. Diabetes & Endocrinology|May 22, 2026
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trialMads M Helsted, Christiane Fonnesbech-Wulff, Nina L Schaltz, et al.
Diabetes, Obesity & Metabolism|October 6, 2025
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trialDavid S Mathiesen, Josefine V Hansen, Aske Høck, et al.
Pageof 2